US Biologics Manufacturers: Export Pipeline

The United States dominates global biologics production. Monoclonal antibodies, vaccines, cell and gene therapies, and biosimilars flow from American facilities to patients in dozens of countries. The US biologics market was valued at USD 203.60 billion in 2025, and the broader US biopharmaceuticals market reached USD 185.45 billion the same year. North America accounts for over 44% of global biologics consumption, with the United States alone representing roughly 40% of the world total.

Yet most US biologics manufacturers, from monoclonal antibody producers and vaccine makers to cell and gene therapy CDMOs, still rely on the same pipeline generation channels they used a decade ago: trade shows, field reps, and distributor networks. As we covered in our broader look at US manufacturing exports and AI outbound, this problem is not unique to biologics, but the technical complexity of biological products makes it especially acute. These channels worked when the biologics landscape was smaller and less competitive. They do not work at the scale and speed the market now demands.

The Biologics Export Opportunity Is Enormous

US pharmaceutical exports reached approximately USD 94.39 billion in 2024, with biologics representing a rapidly growing share. Vaccines alone accounted for an estimated $27 billion in US export value in 2024, while anti-cancer drugs (many of which are monoclonal antibodies) represented roughly $48 billion in exports.

The growth trajectory is steep. The global monoclonal antibodies therapeutics market reached USD 304.52 billion in 2025, on track to surpass USD 1 trillion by 2034. The cell and gene therapy CDMO market in the US was valued at USD 1.62 billion in 2024 and is projected to reach USD 10.34 billion by 2033 at a 23.26% CAGR. The broader biologics manufacturing market is projected to grow from USD 40.1 billion in 2025 to USD 192.5 billion by 2035.

The reality: demand for US biologics manufacturing capability is accelerating worldwide, but the companies with that capability are not reaching international buyers fast enough.

Why Biologics Pipeline Generation Is Uniquely Difficult

Selling biologics manufacturing services or products internationally is not like selling commodity chemicals or metal components. The buying process involves deep technical evaluation, regulatory alignment, and multi-stakeholder decision-making that can stretch across 12 to 24 months.

Regulatory complexity is the first barrier. The FDA, EMA, PMDA (Japan), NMPA (China), and ANVISA (Brazil) each require specific documentation for biological products. A US biologics manufacturer looking to supply a European pharmaceutical company needs to demonstrate CEP filings, GMP compliance under EU standards, and compatibility with the buyer’s quality systems. Communicating all of this through a trade show conversation is nearly impossible.

Buying committees are larger than in traditional pharma. A typical biologics procurement decision involves process development scientists, CMC leads, quality assurance directors, regulatory affairs managers, supply chain heads, and C-suite executives. Reaching one person at a trade show booth does not move a deal forward when five to seven additional stakeholders need to evaluate your capabilities independently.

The technology itself is complex. Monoclonal antibody manufacturing requires specialized bioreactors and purification systems. Cell and gene therapy production demands cleanroom infrastructure and viral vector manufacturing expertise. Vaccine production involves cold chain logistics and batch release testing. Each specialization requires different technical messaging for different buyer roles.

The CDMO Boom Creates Urgent Pipeline Pressure

The contract development and manufacturing organization (CDMO) segment is reshaping how biologics reach international markets. The US biopharmaceutical contract manufacturing market was valued at USD 10.67 billion in 2024 and is growing at a 10.6% CAGR through 2030. North America holds 36.7% of the global biopharmaceutical contract manufacturing market.

The monoclonal antibodies segment leads CDMO market share, while the cell and gene therapy CDMO space is growing at nearly 28% CAGR, fueled by rising approvals of CAR-T and gene therapies.

Here is the pipeline problem: every new CDMO facility needs international clients to fill capacity. Building a $200 million biologics manufacturing facility takes two to three years. Filling it with long-term contracts through trade show leads and field rep relationships takes even longer. The capacity crunch in complex injectable dosage forms, including pre-filled syringes and lyophilized products, is expected to intensify through 2026, creating both an opportunity for CDMOs with available capacity and a challenge for those who cannot communicate their availability to the right buyers quickly enough.

Traditional Channels Are Losing Ground

US biologics exporters have relied on a handful of pipeline generation channels for years. Each one is delivering diminishing returns relative to its cost.

BIO International Convention: The largest global biotech partnering event, drawing over 20,500 companies from 73 countries in 2025. Booth space runs $15,000 to $80,000+ before staffing, travel, and materials. Registration alone is $2,000 to $3,950 per attendee. Converting a 20-minute partnering meeting into a qualified biologics manufacturing lead requires months of follow-up. Cost per qualified lead: $300-$900+.

CPhI Worldwide: Held at Fiera Milano with 62,000+ visitors and 2,400 exhibitors. You invest $30,000 to $100,000+ for three days and hope the right procurement director finds your booth among thousands.

DCAT Week: The Drug, Chemical & Associated Technologies event in New York attracts 10,000+ industry members, with 92% holding senior positions. The audience quality is high, but the event format limits how many meaningful conversations a single team can have in four days.

Field sales representatives: A pharma-experienced BD rep covering a single European or Asian market costs $120,000 to $180,000 annually. Biologics sales require technical depth in upstream/downstream processing, analytical validation, and regulatory documentation. Finding reps with this expertise who also speak German, Japanese, or Mandarin is extremely difficult. Cost per qualified lead: $500-$1,200+.

Distributor and licensing networks: Many US biologics companies enter international markets through licensing agreements or distribution partnerships. These relationships lock you into specific geographies and give the partner control over pricing and customer relationships. When a licensing partner pivots strategy, you lose market access overnight.

All of these channels share one structural weakness: they generate pipeline one conversation at a time in an industry where closing a single deal requires engaging an entire buying committee. The same dynamics we explored in our analysis of US pharma exporters and AI outbound apply here, amplified by the technical complexity and regulatory burden unique to biologics.

How AI Outbound Works for Biologics Manufacturers

AI-powered outbound takes the technical depth and regulatory precision that biologics sales require and delivers it at scale to entire buying committees simultaneously.

Identify the Right Targets

Instead of hoping the right people attend BIO International, AI outbound builds a complete map of your ideal customers globally. For a monoclonal antibody CDMO, that means pharmaceutical companies with late-stage clinical programs needing commercial manufacturing within 18 to 24 months. For a vaccine manufacturer, it could be international procurement agencies and distributors in emerging markets. For a cell and gene therapy producer, the targets are biotech companies with approved or near-approval products that lack in-house manufacturing capacity.

Engage Complete Buying Committees

Each target account gets multi-threaded outreach tailored to individual roles:

• CMC leads and process development scientists receive messaging about your expression systems, upstream/downstream capabilities, and analytical methods
• Quality assurance directors see your GMP compliance record, FDA inspection history, and quality management system certifications
• Regulatory affairs managers learn about your DMF filings, CEP documentation, and experience with submissions to EMA, PMDA, and other agencies
• Supply chain and procurement heads receive information about capacity, lead times, pricing models, and supply continuity
• C-suite executives get a strategic overview of partnership value, including risk mitigation and speed-to-market advantages

Detect Buying Signals in Real Time

AI systems monitor signals that indicate when a biologics company is actively looking for manufacturing partners:

• Clinical trial milestones (Phase 2 to Phase 3 transitions signal near-term manufacturing demand)
• Regulatory approvals in new markets (companies need compliant supply for each geography)
• Capacity expansions or partnerships announced by competitors (companies left out of those deals need alternatives)
• Patent expirations on biologics (biosimilar developers need manufacturing partners quickly)
• Leadership changes in procurement, supply chain, or CMC roles (new decision-makers evaluate new suppliers)

When a European biotech announces positive Phase 3 results for a monoclonal antibody, your outreach can reach their CMC team within days, not months.

Deliver Technical Content Automatically

Biologics buyers require extensive documentation before engaging with a potential manufacturer. AI-powered outbound attaches the right technical assets to the right messages for the right recipients. Process development scientists get your cell line development capabilities. Quality directors get your batch failure rates and audit readiness documentation. Regulatory affairs managers get your DMF cross-references. No more attaching a generic capabilities brochure to every email.

The Cost Comparison Is Decisive

The economics of traditional pipeline generation versus AI outbound are stark for biologics manufacturers.

Channel	Cost Per Qualified Lead	Scalability	Buying Committee Coverage
BIO International / CPhI	$300-$900+	Limited (annual events)	Single contact per interaction
Field sales reps	$500-$1,200+	Very limited (one market per rep)	One to two contacts per account
Distributor networks	Variable + margin loss	Moderate but you lose control	Zero direct access
AI-powered outbound	$150-$300	Unlimited geographies	Full buying committee

At $150 to $300 per qualified lead, AI outbound costs a fraction of what biologics companies currently spend per lead at BIO International or through field reps. More importantly, the system improves over time. Response data feeds back into targeting and messaging, reducing cost per lead as campaigns mature.

For a US biologics CDMO spending $250,000 annually on trade show participation and $360,000 on two international business development reps, the pipeline generated often amounts to 15 to 25 qualified international opportunities per year. AI outbound can generate that volume within the first quarter at a fraction of the cost, with each opportunity already mapped to the full buying committee.

What This Looks Like in Practice

Consider a mid-sized US biologics CDMO with mammalian cell culture capabilities, a viral vector manufacturing suite, and FDA-inspected GMP facilities. Today, they attend BIO International and CPhI annually, rely on two licensing partners in Europe and Asia, and have a three-person business development team focused primarily on domestic accounts.

With AI-powered outbound:

1. The system identifies 350+ pharmaceutical and biotech companies globally with active biologics programs matching the CDMO’s manufacturing capabilities
2. Buying committees are mapped at each target: CMC leads, quality directors, procurement managers, and program directors
3. Personalized outreach reaches each stakeholder with role-specific technical content
4. Signal detection flags a Japanese biotech that just received FDA breakthrough therapy designation for a cell therapy and needs US-based GMP manufacturing capacity
5. Targeted outreach reaches that company’s decision-makers within a week

The result: a consistent, predictable pipeline of international biologics manufacturing opportunities, not the feast-or-famine cycle of annual trade shows.

The Window Is Closing

The biologics manufacturing landscape is consolidating rapidly. Large CDMOs like Samsung Biologics, Lonza, and Catalent continue expanding capacity through acquisitions and facility buildouts. Mid-sized US biologics manufacturers that wait for international buyers to find them at trade shows risk being crowded out.

118 biologics are expected to lose patent protection between 2025 and 2034, according to IQVIA research, opening a $232 billion biosimilar opportunity. Companies developing biosimilars need manufacturing partners now, not in two years when they visit your booth at CPhI.

If you have the capability, the question is whether the right buyers know about you before they sign with someone else.

Getting Started

US biologics manufacturers do not need to abandon trade shows overnight. The practical path forward combines existing channels with AI outbound:

1. Define your biologics ICP: Which therapeutic areas, company stages, and geographies represent your highest-value opportunities?
2. Map the buying committee: For your top 50 target accounts, identify CMC leads, quality directors, regulatory affairs managers, and procurement heads
3. Prepare role-specific technical content: Organize your GMP certificates, FDA inspection history, expression system data, and regulatory filing references for targeted delivery
4. Launch multi-threaded campaigns: Begin outreach to full buying committees, not just the single contact you met at BIO International
5. Measure and compound: Track response rates by role, therapeutic area, geography, and buying signal to continuously improve targeting

At papaverAI, we build AI-powered outbound engines specifically for B2B manufacturers, including biologics producers, CDMOs, and vaccine manufacturers. We handle the infrastructure, targeting, and optimization so your team can focus on manufacturing life-saving biological products.

Frequently Asked Questions

How does AI outbound handle the regulatory sensitivity of biologics sales?

AI outbound manages prospecting and initial engagement. All regulatory claims, GMP documentation, technical specifications, and compliance materials are prepared by your team and delivered through the system with precision targeting. The AI determines which content goes to which stakeholder based on their role and responsibilities. It does not generate or modify regulatory claims, technical data, or compliance documentation. Your regulatory and quality teams maintain full control over what gets communicated.

What types of US biologics companies benefit most from AI outbound?

CDMOs with available capacity, monoclonal antibody manufacturers seeking international buyers, cell and gene therapy producers expanding beyond domestic markets, vaccine manufacturers pursuing international procurement contracts, and biosimilar producers racing to reach buyers before competitors. Any US biologics company with strong manufacturing capabilities but limited international pipeline generation infrastructure is a strong candidate.

How long before AI outbound generates qualified biologics leads?

Most campaigns begin generating qualified responses within 4 to 8 weeks. Given biologics sales cycles of 12 to 24 months for new supplier qualification, first contracts typically close within 9 to 15 months. The critical advantage is building a consistent, predictable pipeline rather than relying on one or two trade shows per year.

Can AI outbound target specific therapeutic areas or modalities?

Yes. Campaigns are built around your specific manufacturing capabilities. A CDMO specializing in ADC (antibody-drug conjugate) manufacturing targets different companies than one focused on viral vector production for gene therapies. The system identifies companies with active programs in your modalities and reaches the technical decision-makers involved in partner selection.

How does AI outbound compare to hiring international business development reps?

A single pharma-experienced BD rep covering one international market costs $120,000 to $180,000 annually and can engage 40 to 60 target accounts per year, reaching one to two contacts per account. AI outbound engages 300+ target accounts across multiple geographies simultaneously, reaching the full buying committee at each. Cost per qualified lead drops from $500-$1,200+ to $150-$300, while coverage expands from one market to many.

---

Ready to build a biologics export pipeline that does not depend on annual trade shows? Get in touch with papaverAI to discuss how AI-powered outbound can connect your manufacturing capabilities with international buyers who need them.